Figures computed from official regulatory filings — .
Ownershipinsiders 0% · institutions 0%
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ENZOLYTICS INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Enzolytics, Inc. a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics, Inc. is based in Plano, Texas.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| EASTERN GLOW INVESTMENTS Ltd | Award | $191.3K | SEC | ||
| KINGSGATE DEVELOPMENT Ltd |
| Other |
| $340K |
| SEC |